Allogene Therapeutics (ALLO) Asset Writedowns and Impairment (2023 - 2025)

Allogene Therapeutics has reported Asset Writedowns and Impairment for 3 years, with the latest figure at $2.4 million in Q2 2025.

• Quarterly Asset Writedowns and Impairment fell 52.36% year-over-year to $2.4 million in Q2 2025, while the trailing twelve-month figure through Dec 2025 was $2.4 million (down 89.28% YoY) and the FY2025 annual result came in at $2.4 million, down 84.84% from the prior year.
• Asset Writedowns and Impairment declined to $2.4 million in Q2 2025 per ALLO's latest filing, from $10.7 million in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $10.7 million in Q3 2024 and troughed at $2.4 million in Q2 2025.
• A 3-year average of $6.2 million and a median of $5.8 million in 2023 frame the typical range for Asset Writedowns and Impairment.
• The widest YoY moves for Asset Writedowns and Impairment: up 52.36% in 2025, down 52.36% in 2025.
• Over 3 years, Asset Writedowns and Impairment stood at $6.5 million in 2023, then jumped by 65.05% to $10.7 million in 2024, then plunged by 77.8% to $2.4 million in 2025.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $2.4 million, $10.7 million, and $5.0 million for Q2 2025, Q3 2024, and Q2 2024 respectively.